Company: HURA
Filing Date: 2025-02-07
Form Type: S-4
Source: 0001193125-25-022803
Chunk: 731

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-02-07
Form: S-4
Chunk 731
---
 either such Milestone Payment in shares of its common stock, the value of the common stock will equal the average of the closing price per share of the Company’s common stock over the twenty (20) trading days following the first public announcement of the applicable event described above.

The milestone payment liability has been estimated using a scenario-based method (or “SBM”). An SBM is an income-based approach under which possible outcomes are identified, the contingent consideration payoff of each outcome is probability weighted, and then a suitable discount rate is used to arrive at the expected present value of the contingent consideration at the valuation date. The probability used in the valuation was based on published research for the probability of success of oncology companies at a similar stage of development as the Company. The discount rate was based on published rates for corporate bonds and the term was based on an estimate of the planned timing of completion of the respective development achievement that would result in payment of the respective milestones.

| Balance – June 30, 2022       |     | $(in thousands) | 163 |
|:------------------------------|:----|:----------------|----:|
| Change in fair value estimate |     |                 |   3 |
| Balance – June 30, 2023       |     |                 | 166 |
| Change in fair value estimate |     |                 |  20 |
| Balance – June 30, 2024       |     |                 | 186 |

8. Stockholders’ equity

Preferred stock

Series C Preferred Stock

|                                                        |     | Series C Preferred Stock |        |   |     |                 |        |   |
|                                                        |     | Numberof shares          |        |   |     | $(in thousands) |        |   |
| Balance – June 30, 2022                                |     |                          | 16,838 |   |     |                 | 12,275 |   |
| Conversion of Series C Preferred stock to common stock |     |                          | (2,630 | ) |     |                 | (1,909 | ) |
| Balance – June 30, 2023                                |     |                          | 14,208 |   |     |                 | 10,366 |   |
| Conversion of Series C Preferred stock to common stock |     |                          |   (540 | ) |     |                 |   (393 | ) |
| Balance – June 30, 2024                                |     |                          | 13,668 |   |